<DOC>
	<DOCNO>NCT01125228</DOCNO>
	<brief_summary>This study compare effectiveness zidovudine ( AZT ) alone vs. zidovudine plus interferon ( IFN ) vs. interferon alone reduce HIV viral load , lessen immune system deterioration , increase time development first opportunistic infection HIV-infected patient . HIV-infected person 18 year age old T4 lymphocyte count 500/mm3 current opportunistic infection may eligible study . Candidates screen medical history , physical examination , blood test , chest X-ray , electrocardiogram , urinalysis , , patient Kaposi sarcoma lesion , measurement , photograph , biopsy lesion . Patients assign receive treatment either zidovudine alone , zidovudine plus interferon interferon alone . They continue treatment one following occur : - Unacceptable side effect , despite dose modification - Development opportunistic infection - Decrease CD4 count 20 percent absolute count le 200/mm3 - Rapid progression Kaposi sarcoma lesion , require alternative therapy - A decision make terminate study Patients follow long term viral load , immune function , development opportunistic infection , disease progression , survival .</brief_summary>
	<brief_title>Effectiveness Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon Treatment HIV</brief_title>
	<detailed_description>Initial Study : THREE ARM ( INTERVENTIONAL ) STUDY This randomize , control phase III protocol , initiated 1988 , first study examine intervention antiretroviral therapy alpha interferon patient HIV infection . It evaluate relative efficacy zidovudine ( AZT ) vs. AZT + alpha interferon ( IFN ) vs. IFN increase time first opportunistic infection , reduce HIV viremia , lessen immune system deterioration HIV-infected person . For AZT alone arm , AZT dose consist ofthe standard regimen 200 mg q4h . Persons AZT + IFN combination arm receive AZT 100 mg q4h IFN begin 1 million unit qd , escalate 2.5 million unit 2 week , increment 2.5 million unit every 2 week . Patients IFN-alone arm begin therapy 5 million unit qd escalate 2.5 million unit increment every 2 week , unless escalation preclude toxicity . Patients evidence HIV infection CD4 countgreater equal 500 randomize one three treatment group . Patients treat assigned medication intolerable toxicity , opportunistic infection , progressive Kaposi 's sarcoma develop , CD4 count decline less 200/mm ( 3 ) . Our statistically significant finding pre-HAART era study show interferon-alpha decreased HIV RNA viral load level , alone combination AZT . Long-Term Follow-up : EXTENSION PHASE ( NATURAL HISTORY STUDY ) Once intervention phase complete , protocol enter long-term follow-up phase evolve longitudinal natural history study . As 2013 work earn distinction follow cohort 25 year . It continue serve important source data regard long-term outcome patient receive anti-HIV treatment , provide information long-term consequence therapy . In addition , store blood cell enable study cut edge research question , relate immune activation , new state-of-the-art laboratory assay .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>INCLUSION CRITERIA : Over 18 year age . T4 lymphocyte count great equal 500/mm3 . Infection HIV document positive ELISA Western blot positive HIV culture positive p24 antigen positive polymerase chain reaction . Absence current opportunistic infection ( defined purpose study : candidiasis , cryptosporidiosis , mycobacterial infection , persistent herpes simplex infection , isosporiasis , cytomegalovirus infection , toxoplasmosis , pneumocystosis , salmonellosis , cryptococcosis ) . Routine clinical method observation perform exclude patient . Afebrile ( Temperature le 38 degree Centigrade orally ) without antipyretic least 72 hour prior enrollment . Performance status 0 , 1 , 2 . Relatively stable clinical condition , deterioration performance status month prior enrollment . Ability give informed consent willing comply procedure visit schedule . Suitability I.V . access schedule blood test . Normal renal function define BUN le equal 30 creatinine less equal 1.5 . Normal hepatic function transaminase alkaline phosphatase less 5 time upper limit normal range . Hemoglobin great equal 10 gm/dl , total granulocyte count great equal 1250/mm ( 3 ) , platelet count great equal 125,000/mm ( 3 ) . No previous therapy KS within month prior enrollment , prior exposure investigational agent . Prior exposure AZT disqualify patient ; however patient stratified basis . EXCLUSION CRITERIA : Patients malignancy Kaposi 's sarcoma specifically exclude study . Pregnant woman , nurse mother , woman childbearing potential employ effective mean contraception abstinence . Patients actively use illicit drug . Patients receive systemically potentially myelosuppressive drug ( TMP/SMX , pyrimethaminesulfa DHPG ) , nephrotoxic agent ( amphotericin B aminoglycosides ) , cytotoxic experimental chemotherapy . Patients history significant depressive disorder . Patients history AIDSdefining opportunistic infection . Subsequent Exclusion Criteria ( Post Enrollment ) After enrollment , patient exclude participation study follow reason : Serious infection clear antibiotic therapy . The occurrence lifethreatening infection , whether consider opportunistic , prompt discontinuation therapy infection 2 week follow successful resolution . Therapy reinitiated unless ( 1 ) investigator 's judgment retreatment either study medication would contraindicate reason ( 2 ) therapy hold 6 week . Decrease percent CD4 le 20 percent absolute CD4 count le 200/mm ( 3 ) 3 consecutive blood test . Systemic allergic reaction either study medication , characterize angioedema , bronchial constriction , anaphylaxis . It principal investigator 's judgment patient ill continue trial . Toxicity necessitate withdrawal . Patient noncompliance : A patient take medication direct keep appointment allow continue study . Rapid lifethreatening progression KS principal investigator believe therapy would patient 's best interest . Voluntary withdrawal : A patient could remove study time . The patient allow withdraw without prejudice . Termination study principal investigator , sponsor , FDA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 20, 2016</verification_date>
	<keyword>AIDS</keyword>
	<keyword>Antiretroviral</keyword>
	<keyword>Kaposi 's Sarcoma</keyword>
</DOC>